Alkermes plc - Ordinary Shares (NQ:ALKS)

44.44 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Alkermes plc - Ordinary Shares

< Previous 1 2 3 Next >

Alkermes to Report Third Quarter Financial Results on November 3, 2026

October 20, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

October 13, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

September 21, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

September 16, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

September 10, 2026

From Alkermes plc

Via Business Wire

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

August 24, 2026

From Alkermes plc

Via Business Wire

Alkermes plc Reports Second Quarter 2026 Financial Results

July 28, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report Second Quarter Financial Results on July 28, 2026

July 14, 2026

From Alkermes plc

Via Business Wire

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

July 13, 2026

From Alkermes plc

Via Business Wire

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

June 17, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

June 15, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

June 04, 2026

From Alkermes plc

Via Business Wire

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 03, 2026

From Alkermes plc

Via Business Wire

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

May 26, 2026

From Alkermes plc

Via Business Wire

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

May 21, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

May 12, 2026

From Alkermes plc

Via Business Wire

Alkermes plc Reports First Quarter 2026 Financial Results

May 05, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report First Quarter Financial Results on May 5, 2026

April 21, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

April 16, 2026

From Alkermes plc

Via Business Wire

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

April 14, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

April 01, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

March 12, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

March 10, 2026

From Alkermes plc

Via Business Wire

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

February 25, 2026

From Alkermes plc

Via Business Wire

Alkermes plc Announces CEO Succession Plan

February 25, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Alkermes plc

Via Business Wire

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

February 12, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

February 11, 2026

From Alkermes plc

Via Business Wire

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

January 06, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 30, 2025

From Alkermes plc

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.